← back to search

Thomas F. Gajewski

University of Illinois Chicago · US
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, and Immune Cell Function and Interaction.
h-index
95
citations
55,796
works
635
NIH funding
primary concept
Medicine
email

Recent publications

Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance).
2026cited by 0position: contributordoi
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
2025cited by 6position: contributordoi
Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy.
2025cited by 1position: contributordoi
1139 The gut microbiota shapes the homeostatic programming of myeloid cells systemically to impact PD-1/PD-L1 blockade therapy
Regular and Young Investigator Award Abstracts 2025cited by 1position: lastdoi
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells.
2025cited by 0position: contributordoi
Supplemental Table 3 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary figure S14 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplementary Figure 8 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary figure S8 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplementary figure S16 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Data from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplementary Figure 5 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary figure S15 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplementary figure S10 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplementary figure S12 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplementary figure S5 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplementary figure S11 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplementary Figure 4 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplemental Table 1 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplemental Table 4 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary Figure 7 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary figure S17 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplemental Table 6 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary Figure 6 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary Figure 3 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplemental Table 2 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary Table S1 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi
Supplemental Table 7 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary Figure 2 from PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
2025cited by 0position: contributordoi
Supplementary figure S6 from Tumor Cell–Intrinsic <i>Decr2</i> Regulates Ferroptosis and Immunotherapy Efficacy
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 54 papers (2019–2026) · 38 papers (2025–2025)Ruxandra Tonea · University of Chicago38 papers (2025–2025) · 26 papers (2022–2025)Jason W. Shapiro · Loyola University Chicago25 papers (2022–2025)Stefani Spranger · Ragon Institute of MGH, MIT and Harvard23 papers (2013–2021)Justin Kline · Palmetto Hematology Oncology22 papers (2013–2025)Jonathan Trujillo · University of Chicago21 papers (2022–2025)Yuanyuan Zha · University of Chicago21 papers (2012–2024)Shuyin Li · University of Chicago20 papers (2025–2025)Blake Flood · Brigham and Women's Hospital20 papers (2025–2025)Hardik Shah · Sylvester Comprehensive Cancer Center20 papers (2025–2025) · 20 papers (2025–2025)Lishi Xie · MDPI20 papers (2025–2025)Yaopeng Li · 20 papers (2025–2025)Ken Hatogai · 20 papers (2025–2025)Tyler A. Jones · University of Chicago20 papers (2025–2025)Alexandra Cabanov · 20 papers (2025–2025)Randy F. Sweis · University of Chicago Medicine Comprehensive Cancer Center18 papers (2025–2025)Ayelet Sivan · 18 papers (2025–2025)